Integration of genomic aberrations to predict clinical outcomes for patients with gastroesophageal adenocarcinoma receiving neoadjuvant chemotherapy
ESMO Gastrointestinal Oncology ESMO Gastrointestinal Oncology: Cellworks TRI predicts OS and DFS beyond clinical factors 2024 Esophageal Cancer
READ MORE